Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Reina-Campos M, Shelton PM, Diaz-Meco MT, Moscat J. Metabolic reprogramming of the tumor microenvironment by p62 and its partners. Biochim Biophys Acta Rev Cancer. 2018;1870(1):88-95.

Reid EG, Looney D, Maldarelli F, Noy A, Henry D, Aboulafia D, et al. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. Blood Adv. 2018;2(24):3618-3626.

Avecilla ST, Goss C, Marionneaux SM, Wright DR, Leiva TD, Tonon J-, et al. Method comparison study of peripheral blood CD34+ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE). Adv Cell Gene Ther. 2018;1(2).

Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, et al. Height, Obesity, and the Risk of -Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(2):193-200.

DeSimone RA, Leung WK, Schwartz J. Transfusion Medicine in a Multidisciplinary Approach to Morbidly Adherent Placenta: Preparing for and Preventing the Worst. Transfus Med Rev. 2018;32(4):244-248.

Viswanathan K, Sung SJ, Scognamiglio T, Hoda RS, Rao RA. Fine needle aspiration of pilomatrixoma: Cytologic features on thinprep and diagnostic pitfalls. Diagn Cytopathol. 2018;46(5):452-455.

Magro CM, Telang GH, Momtahen S. Unilesional Follicular Mycosis Fungoides: Report of 6 Cases and Review of the Literature. Am J Dermatopathol. 2018;40(5):329-336.

Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560(7719):499-503.

Sweeney J, Rao R, Margolskee E, Goyal A, Heymann JJ, Siddiqui MT. Immunohistochemical staining for S100P, SMAD4, and IMP3 on cell block preparations is sensitive and highly specific for pancreatic ductal adenocarcinoma. J Am Soc Cytopathol. 2018;7(6):318-323.

Wang S, Liechty B, Patel S, Weber JS, Hollmann TJ, Snuderl M, et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J Neurooncol. 2018;138(1):183-190.